<div id="readability-page-1"><p>In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Royalty Pharma, with a price target of <span id="expert-recommendation-target">$62.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Gerberry is a 5-star analyst with an average return of <span>18.9%</span> and a 61.32% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Ionis Pharmaceuticals, and Alkermes.</p> <p>Royalty Pharma has an analyst consensus of Strong Buy, with a price target consensus of $59.43.</p></div>

RPRX

LABU

<p>Bank of America Securities has maintained a Buy rating on Royalty Pharma (RPRX) with a price target of $62.00. Analyst Jason Gerberry, a 5-star analyst with an 18.9% average return, highlights Royalty Pharma's Strong Buy consensus and a price target consensus of $59.43. Gerberry also covers other healthcare stocks like BioMarin Pharmaceutical and Ionis Pharmaceuticals.</p>

Tip Ranks

Royalty Pharma PLC - CL

VG Health

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Health Care Select Sector SPDR

Bank of America

BioMarin Pharma

Ionis Pharma

Alkermes

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)